Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
11.57
+0.12 (1.00%)
Nov 5, 2024, 1:19 PM EST - Market open
Viatris Revenue
Viatris had revenue of $3.80B in the quarter ending June 30, 2024, a decrease of -3.11%. This brings the company's revenue in the last twelve months to $15.24B, down -2.32% year-over-year. In the year 2023, Viatris had annual revenue of $15.43B, down -5.14%.
Revenue (ttm)
$15.24B
Revenue Growth
-2.32%
P/S Ratio
0.90
Revenue / Employee
$401,032
Employees
38,000
Market Cap
13.80B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
Dec 31, 2019 | 11.50B | 66.60M | 0.58% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tenet Healthcare | 20.97B |
Universal Health Services | 15.42B |
Solventum | 8.21B |
Incyte | 4.08B |
BioMarin Pharmaceutical | 2.75B |
Genmab | 2.73B |
Revvity | 2.71B |
Exact Sciences | 2.61B |
VTRS News
- 6 hours ago - Viatris Announces Third Quarter 2024 Dividend - PRNewsWire
- 7 days ago - Viatris Named to Forbes' World's Top Companies for Women 2024 List - PRNewsWire
- 7 days ago - Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - PRNewsWire
- 7 days ago - Idorsia announces financial results for the first nine months of 2024 - GlobeNewsWire
- 13 days ago - Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy - Seeking Alpha
- 19 days ago - Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe - PRNewsWire
- 27 days ago - Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD) - PRNewsWire
- 4 weeks ago - Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row - PRNewsWire